Feline 3-HCP
The only USDA-approved, three-year feline core vaccine shown to be effective against feline rhinotracheitis, feline calicivirus, and feline panleukopenia.
Product Description
NOBIVAC® FELINE 3-HCP provides protection for multiple viruses
The only USDA-approved, 3-year core feline vaccine for rhinotracheitis, calicivirus, and panleukopenia.
- The American Association of Feline Practitioners (AAFP) has recommended 3-year vaccination intervals for core antigens such as HCP75
- 100% protection against disease associated with virulent feline panleukopenia virus (FPV) challenge73
- 100% protection against oral ulcerations associated with feline calicivirus (FCV) infection73
- Non-adjuvanted formulation
- Optimal choice for healthy indoor cats
Indications:
Shown to be effective for vaccination of healthy cats 8 weeks of age or older against feline rhinotracheitis, calici, and panleukopenia viruses. Duration of immunity is at least 3 years.
EFFICACY & COMPARISONS
ONLY 3-year labeled HCP vaccine option for cats.
- Proven in a 3-year real-time challenge-of-immunity HCP study73

NOBIVAC® FELINE 3-HCP IS A SAFE CHOICE
- Less likely to produce local and systemic reactions72
- Extended duration of immunity (DOI) to minimize the number of injections
- Nobivac® Feline 3-HCP is the only USDA-approved, 3-year vaccine for rhinotracheitis, calicivirus, and panleukopenia
- 3-year DOI proven in challenge studies73
- American Association of Feline Practitioners (AAFP) has recommended 3-year vaccination intervals for core antigens such as HCP68
ADMINISTRATION AND DOSAGE
- Subcutaneous injection
- Initial 1 mL dose administered at 8 weeks or older
- Booster injection administered 3 to 4 weeks following the initial vaccination
- Cats 12 weeks of age or older should receive two 1 mL doses 3 to 4 weeks apart
- Revaccination with 1 dose is recommended every 3 years
- Available in a 25 x 1 mL dose presentation
DISEASE INFORMATION
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
View More Nobivac® ResourcesReferences
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global